BIODIT AD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.07 BGN | -4.46% |
|
-14.40% | -22.46% |
| 04-29 | Biodit AD Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Biodit AD Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 25.02 | 25.29 | 20.45 |
| Enterprise Value (EV) 1 | 24.89 | 24.25 | 20.69 |
| P/E ratio | -92.2 x | -71.1 x | -79.9 x |
| Yield | - | - | - |
| Capitalization / Revenue | 85.4 x | 34.8 x | 22.6 x |
| EV / Revenue | 85 x | 33.4 x | 22.8 x |
| EV / EBITDA | -155 x | -92.9 x | -163 x |
| EV / FCF | -204,453,840 x | -63,786,104 x | -27,345,956 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 2.28 x | 2.2 x | 1.7 x |
| Nbr of stocks (in thousands) | 13,821 | 13,821 | 14,820 |
| Reference price 2 | 1.810 | 1.830 | 1.380 |
| Announcement Date | 26/04/22 | 10/05/23 | 29/04/24 |
1BGN in Million2BGN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.164 | 0.156 | 0.151 | 0.293 | 0.726 | 0.906 |
| EBITDA 1 | -0.715 | -0.607 | -0.176 | -0.161 | -0.261 | -0.127 |
| EBIT 1 | -0.759 | -0.673 | -0.255 | -0.244 | -0.342 | -0.224 |
| Operating Margin | -462.8% | -431.41% | -168.87% | -83.28% | -47.11% | -24.72% |
| Earnings before Tax (EBT) 1 | -0.654 | -0.637 | -0.279 | -0.286 | -0.4 | -0.278 |
| Net income 1 | -0.567 | -0.577 | -0.253 | -0.268 | -0.377 | -0.256 |
| Net margin | -345.73% | -369.87% | -167.55% | -91.47% | -51.93% | -28.26% |
| EPS | - | -0.0450 | -0.0197 | -0.0196 | -0.0257 | -0.0173 |
| Free Cash Flow | - | -0.2309 | -0.0345 | -0.1218 | -0.3802 | -0.7568 |
| FCF margin | - | -148% | -22.85% | -41.55% | -52.38% | -83.53% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/02/20 | 12/02/20 | 04/05/21 | 26/04/22 | 10/05/23 | 29/04/24 |
1BGN in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.07 | 0.19 | 0.48 | - | - | 0.24 |
| Net Cash position 1 | - | - | - | 0.12 | 1.04 | - |
| Leverage (Debt/EBITDA) | -0.0937 x | -0.3147 x | -2.699 x | - | - | -1.913 x |
| Free Cash Flow | - | -0.23 | -0.03 | -0.12 | -0.38 | -0.76 |
| ROE (net income / shareholders' equity) | - | -5.56% | -2.44% | -2.52% | -3.24% | -2.1% |
| ROA (Net income/ Total Assets) | - | -3.88% | -1.46% | -1.37% | -1.69% | -1.04% |
| Assets 1 | - | 14.87 | 17.3 | 19.62 | 22.26 | 24.69 |
| Book Value Per Share | - | 0.8200 | 0.8000 | 0.8000 | 0.8300 | 0.8100 |
| Cash Flow per Share | - | 0.0200 | 0 | 0.0400 | 0.1300 | 0.0500 |
| Capex 1 | 0.04 | 0.05 | 0 | 0.01 | 0 | 0.02 |
| Capex / Sales | 22.56% | 33.33% | 1.99% | 3.75% | 0.41% | 1.88% |
| Announcement Date | 12/02/20 | 12/02/20 | 04/05/21 | 26/04/22 | 10/05/23 | 29/04/24 |
1BGN in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.46% | 8.79M | |
| -27.23% | 509M | |
| +4.55% | 374M | |
| -14.39% | 327M | |
| -20.91% | 79.71M | |
| +25.53% | 50.02M |
- Stock Market
- Equities
- BDT Stock
- Financials Biodit AD
